for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cancer Genetics Inc

CGIX.OQ

Latest Trade

6.99USD

Change

1.48(+26.86%)

Volume

172,387

Today's Range

5.85

 - 

7.18

52 Week Range

2.01

 - 

20.59

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.51
Open
5.91
Volume
172,387
3M AVG Volume
15.35
Today's High
7.18
Today's Low
5.85
52 Week High
20.59
52 Week Low
2.01
Shares Out (MIL)
2.10
Market Cap (MIL)
14.68
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Cancer Genetics Q3 Earnings Per Share $0.98

Cancer Genetics Announces 1-For-30 Reverse Stock Split

Cancer Genetics Posts Q2 Loss Per Share Of $0.01

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cancer Genetics Inc

Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services and molecular markers. Through its subsidiary, the Company offers preclinical test systems. The Company offers discovery services to the pharmaceutical industry, biotechnology companies and academic research centers. The Company provides the tools and testing methods for companies and researchers to identify new molecular- and biomarker-based indicators for disease and to determine the pharmacogenomics, toxicity and efficacy of therapeutic candidate compounds. Its discovery services include development of both xenograft and syngeneic animal models, toxicology and genetic toxicology services, pharmacology testing, pathology services, and validation of biomarkers for diseases including cancers. It also provides consulting, guidance and preparation of samples.

Industry

Biotechnology & Drugs

Contact Info

201 State Rt 17 Fl 2

+1.201.5289200

http://www.cancergenetics.com

Executive Leadership

John G. Pappajohn

Non-Executive Chairman of the Board

John A. Roberts

President, Chief Executive Officer

Glenn Miles

Chief Financial Officer

Jane Houldsworth

Vice President - Research & Development

Raju S. K. Chaganti

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1.20
Price To Book (MRQ)
1.97
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
33.24
LT Debt To Equity (MRQ)
1.98
Return on Investment (TTM)
-110.64
Return on Equity (TTM)
-35.91

Latest News

Latest News

BRIEF-Cancer Genetics Says Appointed John Roberts As CEO And President

* CANCER GENETICS SAYS ON APRIL 30, BOARD APPOINTED JOHN ROBERTS AS COMPANY'S CEO AND PRESIDENT - SEC FILING Source: (https://bit.ly/2w2ruOW) Further company coverage:

BRIEF-Cancer Genetics Reports Q4 Loss Per Share Of $0.35

* CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES

BRIEF-Cancer Genetics Receives Non-Dilutive Funding Of $1.1 Mln

* CANCER GENETICS RECEIVES NON-DILUTIVE FUNDING OF $1.1 MILLION THROUGH NEW JERSEY TECHNOLOGY BUSINESS TAX CERTIFICATE TRANSFER (NOL) PROGRAM

BRIEF-Stonepine Capital Management Reports 5 Percent Passive Stake In Cancer Genetics

* STONEPINE CAPITAL MANAGEMENT REPORTS 5 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS ON DEC 12 - SEC FILING Source: (http://bit.ly/2p5v6Mx) Further company coverage:

BRIEF-Cancer Genetics Prices $7 Million Registered Direct Offering

* CANCER GENETICS PRICES $7 MILLION REGISTERED DIRECT OFFERING

BRIEF-Cancer Genetics Q3 loss per share $0.15

* Cancer genetics reports record third quarter 2017 revenue and 134% increase in contracted bookings from major biotech and pharmaceutical companies

BRIEF-Cancer Genetics to acquire vivoPharm

* Cancer Genetics announces transformative and accretive acquisition of vivoPharm, a global oncology & immuno-oncology discovery services company

BRIEF-Cancer Genetics reports Q2 loss per share $0.16

* Cancer Genetics Inc announces second quarter 2017 financial results, accretive acquisition and capital raise

BRIEF-DIA elects Cancer Genetics Inc's John A. (Jay) Roberts as Chairman of board

* DIA elects Cancer Genetics Inc's John A(Jay) Roberts as chairman of DIA board of directors

BRIEF-Cancer Genetics files for mixed shelf of up to $100 mln

* Cancer Genetics inc files for mixed shelf of up to $100 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Cancer Genetics partners with Ventana Medical Systems for market access to predictive biomarker test

* Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to ensure market access to predictive biomarker test for new immuno-oncology (io) therapy for advanced bladder cancer

BRIEF-CANCER GENETICS INC REPORTS Q1 LOSS PER SHARE $0.51

* CANCER GENETICS INC ANNOUNCES 15% REVENUE INCREASE IN FIRST QUARTER OF 2017 OVER 2016 ON STRONG ORGANIC GROWTH WHILE CONTINUING ON PATH TO PROFITABILITY

BRIEF-Cancer Genetics and Mendel.ai announce strategic partnership

* Cancer Genetics, Inc. and Mendel.ai announce strategic partnership enabling artificial intelligence in precision medicine to drive personalized treatment and accelerate clinical trial matching for cancer care

BRIEF-Cancer Genetic Q4 loss per share $0.15

* Cancer Genetics, Inc. Announces record revenue for fourth quarter and full-year 2016 and provides 2017 business update

BRIEF-Cancer Genetics says received approval for a $1 mln gross tax credit from New Jersey technology business tax certificate transfer program

* Cancer Genetics Inc - received approval for a $1.0 million gross tax credit from New Jersey technology business tax certificate transfer program Source text for Eikon: Further company coverage:

BRIEF-CANCER GENETICS LAUNCHES FOCUSED GENOMIC PANEL FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME

* HAS LAUNCHED A FOCUSED GENOMIC PANEL FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME (HBOC)

BRIEF-Cancer Genetics announced strategic collaboration with Lantern Pharma

* Announced a strategic collaboration with lantern pharma, inc

BRIEF-Cancer Genetics announces agreements to develop liquid biopsy programs

* Cancer genetics, inc. Announces multiple agreements & collaborations to develop liquid biopsy programs with leading biopharma companies

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up